Elias Jabbour

Research interests

Publications

• Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

  New England Journal of Medicine · 2024 · 10.1056/nejmoa2406526

• Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-022-02103-8

• Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

  American Journal of Hematology · 2022 · 10.1002/ajh.26642

• International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

  Blood · 2022 · https://doi.org/10.1182/blood.2022015850

• Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

  The Lancet Haematology · 2022 · 10.1016/s2352-3026(22)00319-2

• Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

  Cancer Discovery · 2021 · 10.1158/2159-8290.cd-20-1465

• Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03736

• De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

  Cancer · 2021 · 10.1002/cncr.33458

• Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

  American Journal of Hematology · 2020 · https://doi.org/10.1002/ajh.25792

• FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

  Leukemia · 2020 · 10.1038/s41375-019-0694-3

• 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30210-6

• Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-19119-8

• Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32334-5

• Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

  Cancer · 2019 · https://doi.org/10.1002/cncr.32116

• Ibrutinib and Venetoclax for First-Line Treatment of CLL

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1900574

• Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0774

• Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

  The Lancet Haematology · 2018 · 10.1016/s2352-3026(18)30176-5

• The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

  Cancer · 2018 · https://doi.org/10.1002/cncr.31896

• Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30011-1

• Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

  American Journal of Hematology · 2018 · https://doi.org/10.1002/ajh.25011

• Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

  The Lancet Haematology · 2017 · https://doi.org/10.1016/s2352-3026(17)30103-5

• Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

  American Journal of Hematology · 2017 · https://doi.org/10.1002/ajh.25000

• Adult Acute Lymphoblastic Leukemia

  Mayo Clinic Proceedings · 2016 · 10.1016/j.mayocp.2016.09.010

• Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

  Blood · 2016 · https://doi.org/10.1182/blood-2015-08-661702

• Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

  Blood · 2016 · https://doi.org/10.1182/blood-2016-07-726588

• Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

  Blood · 2016 · 10.1182/blood-2016-09-736686

• TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

  Cancer · 2016 · 10.1002/cncr.30203

• Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

  Blood · 2016 · 10.1182/blood-2016-03-707562

• Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

  The Lancet Haematology · 2015 · https://doi.org/10.1016/s2352-3026(15)00048-4

• Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00038-8

• Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00207-7

• Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

  Haematologica · 2015 · 10.3324/haematol.2014.118588

• New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

  Cancer · 2015 · 10.1002/cncr.29383

• BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

  Cancer Cell · 2014 · https://doi.org/10.1016/j.ccr.2014.07.006

• Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

  Blood · 2013 · https://doi.org/10.1182/blood-2013-06-511592

• Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

  Cancer · 2013 · 10.1002/cncr.28136

• Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(11)70386-2

• Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

  Blood · 2012 · 10.1182/blood-2011-08-358135

• Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.34.4226

• Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

  Cancer · 2010 · 10.1002/cncr.25247

• Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

  Blood · 2010 · https://doi.org/10.1182/blood-2010-03-276485

• Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.25.4896

• Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.25.4920

• Evolution of decitabine development

  Cancer · 2008 · 10.1002/cncr.23463

• Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

  Blood · 2007 · 10.1182/blood-2007-03-080838

• Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

  Blood · 2006 · https://doi.org/10.1182/blood-2006-03-009142

• Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

  Leukemia · 2006 · https://doi.org/10.1038/sj.leu.2404318

• Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

  Cancer · 2006 · https://doi.org/10.1002/cncr.21723

Current projects

No projects listed.